TRexBio prices $116.7 million initial public offering

TRexBio, a clinical-stage biotechnology company specializing in tissue Treg biology, has announced the pricing of its initial public offering. The company will offer 8,333,334 shares of common stock at an initial price of $14.00 per share.

The gross proceeds from the offering are expected to be approximately $116.7 million, before deducting underwriting discounts, commissions, and other expenses. TRexBio’s common stock is scheduled to begin trading on the Nasdaq Global Select Market on October 9, 2026, under the ticker symbol ‘TRXB’. The offering is expected to close on October 13, 2026.

Underwriters have been granted a 30-day option to purchase up to an additional 1,250,000 shares of common stock at the initial offering price. J.P. Morgan, Evercore ISI, Cantor, and Stifel are serving as the lead book-running managers, with Wedbush PacGrow also acting as a book-running manager.